Morinaga Milk (Nachrichten) Industry Co, says that it has attained self-affirmed GRAS (generally recognized as safe) status for its Bifidobacterium longum BB536 probiotic ingredient. After a comprehensive evaluation of research and toxicology data by an independent panel of scientists, Bifidobacterium longum BB536 was found to be safe for use in food products and supplements, says the Japan-headquartered company.
"Bifidobacterium longum BB536 has been one of the best-selling probiotic ingredients in Japan since its introduction in 1977, and this recently obtained GRAS status allows manufacturers in the USA more freedom to add this beneficial ingredient to a broad range of consumer products," stated a Morinaga Milk Industry spokesperson, adding: "securing GRAS status in the USA underscores our ongoing commitment to ensuring regulatory compliance for our global customer base, as well as our dedication to developing highly functional and safe ingredients."
To date, more than 50 scientific reports confirm the effectiveness of Bifidobacterium longum BB536 in enhancing overall human health, including improving intestinal health, supporting healthy cell growth, preventing diarrhea, promoting immunopotentiation and modulation of immune balance, to name a few. The strain, which is isolated from a healthy infant, is known for its high stability, making it an ideal option for use in a variety of food and supplement applications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze